Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab
- 6 December 2023
- journal article
- research article
- Published by Wiley in International Journal of Dermatology
- Vol. 63 (2) , 196-200
Abstract
Background: Little real‐world experience regarding the use of baricitinib, an oral selective JAK1/JAK2 inhibitor, for treating moderate to severe atopic dermatitis (AD) has been reported.Methods: This study aimed to assess the overall outcomes in Korean patients with AD treated with baricitinib. All patients with moderate to severe AD treated with baricitinib between June 2021 and June 2022 were included, and their cases were retrospectively analyzed using medical records. Patients with moderate to severe AD, aged ≥18 years who had failed previous therapies, including those who demonstrated unsatisfactory improvement with dupilumab, were prescribed baricitinib. Patients whose follow‐up period was <8 weeks were excluded. The dermatologist evaluated the AD status, including eczema area and severity index (EASI), itch Numeric Rating Scale, and improvement of remaining lesions despite dupilumab therapy.Results: We analyzed 34 AD patients who received baricitinib. Twelve patients treated with dupilumab were additionally prescribed baricitinib due to unsatisfactory treatment effects and demonstrated improvement in the remaining lesions despite dupilumab treatment. Their itching improved after 1.4 weeks. Among them, eight patients (66.7%) had head and neck dermatitis, and seven of them demonstrated improvement after the coadministration of baricitinib. Among the other 22 patients who were prescribed baricitinib only, 10 patients (45.5%) achieved EASI 75 at 8 weeks, with five (22.7%) revealing EASI 90.Conclusions: Overall, baricitinib was well tolerated and resulted in clinical improvement in AD patients in a real‐world clinical setting. Additionally, baricitinib may be beneficial in treating lesions refractory to dupilumab therapy.Keywords
This publication has 11 references indexed in Scilit:
- Treatment of Atopic Dermatitis with Baricitinib: First Real-life ExperienceActa Dermato-Venereologica, 2022
- Real‐world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single‐center retrospective studyThe Journal of Dermatology, 2022
- Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinibJournal of the European Academy of Dermatology and Venereology, 2021
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrialsBritish Journal of Dermatology, 2020
- Characterizing dupilumab facial redness: A multi-institution retrospective medical record reviewJournal of the American Academy of Dermatology, 2020
- Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013Journal of the American Academy of Dermatology, 2019
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Dupilumab: First Global ApprovalDrugs, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012